Phase II study of XL184 (cabozantinib) in recurrent or metastatic endometrial cancer: A trial of the PMH, Chicago, and California Phase II Consortia
| Autor: | Helen Mackay, Amit M. Oza, Michelle K. Wilson, Stephen Welch, Lynda D. Roman, Lainie P. Martin, Katie Allen, John Wright, Cristina Martin-Lorente, Lisa Wang, Helen Steed, Neesha C. Dhani, Judy Quintos, Hal W. Hirte, Marcus O. Butler, Stephanie Lheureux |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty Pathology Poor prognosis Cabozantinib biology business.industry Angiogenesis VEGF receptors Phases of clinical research Recurrent Endometrial Cancer chemistry.chemical_compound chemistry Internal medicine medicine biology.protein business Metastatic endometrial cancer |
| Zdroj: | Journal of Clinical Oncology. 32:TPS5629-TPS5629 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2014.32.15_suppl.tps5629 |
| Popis: | TPS5629 Background: Recurrent endometrial cancer (EC) has a poor prognosis with few therapeutic options. Targeting angiogenesis through VEGF inhibition has demonstrated real but limited efficacy. S... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|